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Abstract
Introduction: Neuroanatomic features associated with antidepressant treatment outcomes in older depressed individuals
are not well established. This study used diffusion tensor imaging to examine frontal white matter structure in depressed
subjects undergoing a 12-week trial of sertraline. We hypothesized that remission would be associated with higher frontal
anisotropy measures, and failure to remit with lower anisotropy.
Methods: 74 subjects with Major Depressive Disorder and age 60 years or older were enrolled in a twelve-week open-label
trial of sertraline and completed clinical assessments and 1.5T magnetic resonance brain imaging. The apparent diffusion
coefficient (ADC) and fractional anisotropy (FA) were measured in regions of interest placed in the white matter of the
dorsolateral prefrontal cortex, anterior cingulate cortex, and corpus callosum. Differences in ADC and FA values between
subjects who did and did not remit to treatment over the study period were assessed using generalized estimating
equations, controlling for age, sex, medical comorbidity and baseline depression severity.
Results: Subjects who did not remit to sertraline exhibited higher FA values in the superior frontal gyri and anterior
cingulate cortices bilaterally. There were no statistically significant associations between ADC measures and remission.
Conclusions: Failure to remit to sertraline is associated with higher frontal FA values. Functional imaging studies
demonstrate that depression is characterized by functional disconnection between frontal and limbic regions. Those
individuals where this disconnection is related to structural changes as detected by DTI may be more likely to respond to
antidepressants.
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Introduction
Depression in older populations can differ from depression in
younger adult individuals and is often associated with chronic
medical illness, disability, and cognitive impairment. It is also
associated with aging-related brain changes including the presence
of hyperintense lesions, bright areas occurring in the brain
parenchyma as seen on T2-weighted magnetic resonance imaging
(MRI). These changes are primarily ischemic in origin [1], and
although are observed in normal aging, are often more severe in
older depressed individuals [2].
The relationship between these hyperintense lesions and antide-
pressant treatment outcomes is unclear. Several studies have
concluded that greater hyperintense lesion severity is associated
with poorer response to antidepressants [3–7]. Greater hyperinten-
sity severity is additionally associated with significantly more adverse
drug reactions [8], which may result in early drug discontinuation or
inability to increase doses to therapeutic levels. In contrast, other
studies have not found a relationship between cross-sectional lesion
severity and acute antidepressant outcomes [9–16], although
relationships may exist between longitudinal change in lesion
severity and longer-term course of depression [11].
More recent work investigating late-life depression has utilized
diffusion tensor imaging (DTI). DTI can quantify water diffusion,
which in living tissue is constrained by neuronal integrity and
modulated by myelin [17]. DTI measures include the apparent
diffusion coefficient (ADC), a general measure of diffusion which
may serve as a surrogate marker for fiber density [18], and
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has been proposed to be a surrogate marker for white matter
orientation and organization. Similar to what is observed in old
stroke regions, white matter hyperintense lesions increase ADC and
decrease anisotropy [19], and greater hyperintense lesion severity is
associated with more widespread alterations in DTI measures even
in normal appearing white matter [20]. Although several studies
have reported that depressed elders exhibit reduced frontal and
temporal anisotropy [21–24], this technique has not been used as
extensively to study treatment response. One group has examined
the relationship between DTI measures and antidepressant response
in geriatric depression, associating failure to achieve remission with
reduced fractional anisotropy in multiple regions, including the
cingulate gyrus and dorsolateral prefrontal cortex [25,26].
The purpose of this study was to use DTI to examine if
measures of frontal white matter microstructure were associated
with acute 12-week response to sertraline. We hypothesized that
lower fractional anisotropy (FA) and higher diffusivity (measured
as ADC), a pattern of findings associated with both chronic stroke
and hyperintense lesions [19,20], would be associated with failure
to achieve remission. In turn, we hypothesized that individuals
who remitted would exhibit higher frontal FA measures.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Sample
Subjects were recruited from advertisements and outpatient
clinical referrals at Duke University Medical Center. To be eligible,
subjects had to be age 60 years or older, meet DSM-IV criteria for
Major Depressive Disorder without psychosis as assessed through
clinical evaluation and the Structured Clinical Interview for DSM-
IV (SCID) [27], and exhibit a baseline Montgomery-Asberg
Depression Rating Scale [28] score of 18 or greater. Exclusion
criteria included: 1) any MRI contraindications; 2) comorbid Axis I
diagnosis, including current substance abuse or bipolar disorder; 3)
active suicidality; 4) current psychotic symptoms, 5) severe or
unstable medical conditions; 6) primary neurological disorders
including dementia or stroke; 7) Mini-Mental State Examination
(MMSE) [29] score,24; 8) current depressive episode that failed to
respond to adequate trials of two prior antidepressants administered
for at least 6 weeks at therapeutic doses, or had failed an adequate
trial of sertraline; 9) current psychotherapy.
All study procedures were explained to each participant, and
those who provided written informed consent were enrolled. The
study was approved by the Duke University Health System
Institutional Review Board.
Study Design and Clinical Measures
Baseline data acquisition included assessing demographic data,
depression severity using the MADRS, and severity of medical
burden using the Cumulative Illness Rating Scale (CIRS) modified
for geriatric populations [30]. Age of depression onset was
ascertained through the SCID and review of medical records.
After screening, subjects taking antidepressant medications at
doses approved to treat depression underwent a washout period of
up to two weeks, while those taking lower doses had the
antidepressant stopped without a washout. Eleven subjects had
antidepressants discontinued after enrollment, while two had St.
John’s Wort discontinued. The study protocol allowed limited use
of zolpidem or zaleplon for sleep, or lorazepam for anxiety.
Subjects on other concomitant medications for medical indica-
tions, sleep, or anxiety could continue them provided doses
remained stable. Eleven subjects required hypnotics for sleep,
seven required benzodiazepines for anxiety, and seven subjects
were on anticonvulsants or benzodiazepines for medical indica-
tions such as neuropathy or restless legs syndrome.
After completing any needed washout, subjects received
sertraline for twelve weeks. They were generally started at
25 mg for a few days to rule out drug sensitivity, and then
increased to 50 mg daily. Subjects were assessed at 2, 4, 6, 8, and
12 weeks. A dose increase of 50 mg was allowed at each visit, up to
a possible maximum dose of 200 mg daily, and the decision to
titrate the dose was guided by the Clinical Global Impression –
Severity scale (CGI-S) [31]. Subjects with a CGI-S of 3 or greater
had a dose increase unless there was a concern for tolerability.
Subjects with a CGI-S of 2 could be titrated at investigator
discretion, and a CGI-S of 1 was considered to be in remission. If a
dose increase resulted in intolerable side effects, the dose could be
reduced to the previously tolerated level. Depression severity was
assessed at each visit using the MADRS.
MRI Acquisition and Processing
Subjects were imaged with a 1.5 T whole-body, research-
dedicated MRI (Signa, GE Healthcare) using a standard head
(volumetric) radiofrequency coil. The scanner alignment light was
used to adjust head tilt and rotation so the axial plane light passed
across the canthomeatal line and the sagittal lines were aligned
with the center of the nose. A rapid sagittal localizer scan was
acquired to confirm alignment. MRI was obtained within the first
two weeks of study participation, typically at the first follow-up
visit after initiating study drug.
The diffusion tensor images were acquired using a single shot 2D
diffusion tensor echoplanar pulse sequence inthe axial plane with a
32 cm field-of-view, 3 mm slice thickness (no gaps between slices),
relaxation time (Tr)=6000, excitation time (Te)=100, 128
(phase)6128 (frequency), full imaging bandwidth=180 KHz, 4
signal averages, 6 diffusion directions, each with a b-value of
1000 sec/mm
2 plus an acquisition with b=0 using the Basser
scheme [32].
Diffusion tensor images were processed using custom programs
run on MATLAB software (version 7, The MathWorks, Natick,
MA) that calculated the diffusion tensor eigenvalues in each voxel
[33]. FA and ADC images were calculated, and regions-of-interest
(ROIs) were placed by a single analyst (WDT) using Analyze
software (version 6.5, Mayo Clinic). Scans were coded with no
identifiable information, and the analyst was blinded to subject
identity and treatment outcome.
Oval ROIs of identical size (45.7 mm
2) were used to measure
FA and ADC values. The same ROI was used for both measures,
and all ROIs were placed on axial slices. Hyperintense lesions
were avoided for all ROI placements. This decision was made
based on the observation that hyperintensities can have strong
effects on DTI measures that is not representative of the DTI
measures of surrounding white matter [19]. There were no cases
where the presence of hyperintense lesions prevented appropriate
ROI placement according to ROI placement procedures.
ROI placement procedures have been previously described
[20,21]. The superior (SFG) and middle frontal gyri (MFG) ROIs
were placed halfway between the precentral sulcus and anterior
boundary of the brain, on the most inferior slice where both gyri
were visible as separate structures. The anterior cingulate cortex
(ACC) ROIs were placed in the white matter lateral to the
cingulated gyrus, on the most inferior slice where the anterior
horns of the lateral ventricle were still visible. For the corpus
Anisotropy in Depression
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slice ventral to the slice where it was divided by the longitudinal
fissure. Results from these two separate corpus callosum ROIs
were averaged together to create a composite measure. We used
the corpus callosum as a control region that we did not expect to
be associated with antidepressant outcomes as it is a region of high
anisotropy that was not different between depressed and
nondepressed elders in previous studies [21].
Reliability was established by repeated measurements on
multiple DTI scans. Intraclass correlation coefficients (ICCs) of
FA measures were: left ACC, 0.910; right ACC, 0.992; left SFG,
0.991; right SFG, 0.985; left MFG, 0.975; right MFG, 0.983; left
corpus callosum, 0.971; right corpus callosum, 0.934. ICCs for
ADC measures (using the same ROIs as the FA measures) were:
left ACC, 0.945; right ACC, 0.957; left SFG, 0.978; right SFG,
0.987; left MFG, 0.931; right MFG, 0.893; left corpus callosum,
0.751; right corpus callosum, 0.799.
Statistical Analysis
SAS software (version 9.1, SAS Institute, Cary, NC) was used for
allstatisticalanalyses.RemissionwasdefinedasachievingaMADRS
of 10 or less at any assessment, as this cutoff has been shown to
provide a valid definition [34]. Bivariate analyses of demographic
and neuroimaging data were conducted between remitted and
nonremitted groups, using the chi-square test for categorical
variables and two-tailed t-test for continuous variables, or the
Satterthwaite t-test if variances were not equal. Normality of
neuroimaging data was assessed both graphically and by Wilks test.
Primary analyses used the GENMOD procedure in SAS to
develop generalized estimating equation (GEE) models [35] using an
exchangeable correlation structure which examined the relationship
between the repeated outcome measure of failure to remit at each
assessment point and the independent variables. For missing data,
the GEE models assume missing completely at random (MCAR).
The dependent measure was the repeated measure dichotomous
variable of remitted or not remitted, and we modeled the probability
of failing to remit. Independent variables included the DTI measure,
baseline depression severity measured with the MADRS, age, sex,
medical comorbidity measured using the CIRS, and a variable
accounting for which assessment period was being evaluated
(baseline, 2-, 4-, 6-, 8- or 12-week). These covariates were selected
for the model as they were either significantly different between the
remitting and non-remitting groups (age, baseline MADRS) or have
been previously associated with antidepressant outcomes in late-life
depression (medical comorbidity, [36]; sex, [37]). In an exploratory
step, we also tested for a DTI measure – age interaction and a DTI
measure – baseline MADRS interaction effect on remission.
Multicolinearity between covariates was assessed in models by
examiningvarianceinflationfactors(VIF);allVIFswerelessthan30.
Separate models were created to examine each DTI measure. We
did not control for multiple comparisons.
In secondary analyses, we sought to examine if DTI measures
were associated with time to remission, an approach used by others
[25]. This survival model used the PHREG procedures in SAS [38],
examining the time to first remission or last assessment, at which
point subjects were censored. Independent variables included DTI
measures, age, baseline MADRS score, sex, and CIRS score.
Results
101 depressed subjects signed consent and enrolled in the study
between January 2002 and March 2006; 74 of those subjects are
included in this analysis (Figure 1). 35 subjects were female and 39
were male, with a mean age of 68.1 years (range 60–95 years,
standard deviation=SD=7.3 years). The group’s mean initial
MADRS score was 25.4 (SD=4.2, range 18–37); at study
completion, the mean final MADRS score was 11.5 (SD=7.9,
range 0–42), with a mean sertraline daily dose of 102.0 mg
(SD=37.6 mg, range 25 mg–200 mg).
Over the course of the twelve-week study, 37 subjects achieved a
MADRS score of 10 or less and achieved remission, while 37
subjects did not. 67 subjects completed all 12 weeks of the study.
Four subjects completed only 4 weeks, 1 completed only 6 weeks,
and 2 completed only 8 weeks. All of the subjects who withdrew
early were classified as not achieving remission, except one of the
subjects who completed only 8 weeks who did remit. Remitted
subjects were younger and less severely depressed at baseline
(Table 1). We next tested for bivariate differences in unadjusted
FA and ADC measures between subjects who did and did not
remit (Table 2). In these analyses, the only measure significantly
different between remitted and nonremitted groups was the FA
value of the right anterior cingulate cortex.
Table 3 details the results of models examining the relationship
between failure to remit and regional FA, while also controlling for
baseline depression severity, age, sex, and medical comorbidity as
measured with the CIRS. In these models, higher anisotropy of the
white matter of the superior frontal gyri bilaterally and anterior
cingulate cortices bilaterally was significantly associated with
failure to remit. In these models where FA was significantly
associated with lack of remission, higher baseline MADRS
(p,0.01 all models) and greater age (p,0.05 all models) were
also associated with nonremission, while neither gender nor CIRS
score reached a level of statistical significance in any model.
Similar models were created examining the relationship between
ADC values and nonremission; however ADC was not associated
with nonremission in any model (data not shown). When DTI-age
and DTI-MADRS interactions were included, these terms did not
reach statistical significance in any model.
Finally, we used an approach similar to that found in a previous
report [25] to determine if these DTI measures were associated
with a time to first remission. The 37 subjects who remitted has a
mean time to remission of 6.8 weeks (SD=2.8 weeks, median=6
weeks). In models controlling for baseline MADRS score, age, sex,
and CIRS score, no DTI measure was significantly associated with
time to remission (data not shown).
Figure 1. Subject flow. Details of subject enrollment and why
excluded from the present study.
doi:10.1371/journal.pone.0003267.g001
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Contrary to our hypothesis, we found that higher FA measures,
not lower, were associated with a failure to achieve remission.
These measures were of the anterior cingulate and superior frontal
gyrus, regions previously identified as exhibiting depression-related
differences on DTI [21] and associated with antidepressant
response in functional imaging studies [39]. These relationships
were statistically significant after controlling for age, sex, baseline
depression severity, and medical comorbidity. We found no
association between ADC and remission.
These results are discrepant with the two other published studies
examining the relationship between antidepressant outcomes and
white matter anisotropy [25,26]. These studies, conducted by the
same group, found that individuals who failed to achieve remission
exhibited lower anisotropy inmultipleregions,including the anterior
and posterior cingulate cortex and the dorsolateral prefrontal cortex.
In contrast, we found lower likelihood of remission to be associated
with increased frontal anisotropy. Despite examining smaller
samples (the larger study included 48 evaluable subjects, while we
examined 78), those studies had a similar 12-week study design using
serotonin reuptake inhibitors and comparable demographic charac-
teristics. One methodological difference is the use of a voxel-based
analysis of the anisotropy data, while this study used a region-of-
interest approach. The difference in conclusions with these studies
may be related to the differences in sample size or methodology, but
may also reflect heterogeneity in the pathophysiology of depression
in older subjects.
This discrepancy across studies raises questions about what
biological factors most strongly contribute to DTI measures. ADC
is an overall measure of water diffusion, and given the size of
imaging voxels relative to the microstructural environment,
includes intracellular and extracellular spaces [40]. The relation-
ship between brain microstructure and FA values are likely
multifactorial. Current hypotheses of what factors contribute to
Table 1. Demographic characteristics between subjects who did and did not remit.
Remitted (N=37) Nonremitted (N=37) Test Result df p value
Age 65.8 (5.7) 70.5 (8.0) t=2.94 64.9 0.0045
Sex (% Female) 43.2% (16/37) 48.6% (18/37) x
2=0.49 1 0.4849
Race (% Caucasian) 94.6% (35/37) 94.6% (35/37) - 1 1.0000
Age of Onset 55.0 (15.8) 55.0 (16.4) t=0.00 72 1.0000
CIRS 6.5 (2.8) 7.4 (3.6) t=1.26 72 0.2133
MMSE 28.3 (1.7) 27.6 (1.7) t=1.74 72 0.0857
MADRS, baseline 24.4 (3.8) 26.4 (4.5) t=2.05 72 0.0438
MADRS, final 5.4 (2.9) 17.6 (6.4) t=10.51 50.3 ,0.0001
Final Sertraline Dose 97.8 (36.5) 106.1 (38.8) t=0.93 72 0.3578
Age and age of onset presented in years. Final of sertraline is in milligrams. Continuous variables presented as mean (standard deviation). Two-tailed pooled t-tests used for
continuous variables (Satterthwaite t-test for unequal variances), chi-square test for sex, and Fisher’s exact test for race. CIRS=Cumulative Illness Rating Scale;
MADRS=Montgomery-Asberg Depression Rating Scale.
doi:10.1371/journal.pone.0003267.t001
Table 2. Unadjusted differences in DTI measures between




(N=37) t valuedf p value
FA values
N SFG, left 0.408 (0.080) 0.421 (0.082) 0.80 72 0.4284
N SFG, right 0.392 (0.069) 0.402 (0.080) 0.53 72 0.6007
N MFG, left 0.283 (0.064) 0.262 (0.046) 1.54 72 0.1284
N MFG, right 0.268 (0.052) 0.264 (0.049) 0.34 72 0.7351
N ACC, left 0.365 (0.063) 0.374 (0.076) 0.56 72 0.5802
N ACC, right 0.332 (0.055) 0.368 (0.072) 2.44 72 0.0170
N CC, genu 0.423 (0.070) 0.454 (0.101) 1.51 63.9 0.1343
ADC values
N SFG, left 76.1 (5.8) 77.4 (11.2) 0.63 53.8 0.5308
N SFG, right 76.2 (5.2) 77.2 (11.4) 0.48 50.1 0.6344
N MFG, left 77.5 (7.3) 79.0 (6.1) 0.91 72 0.3643
N MFG, right 79.6 (6.2) 80.1 (5.8) 0.30 72 0.7636
N ACC, left 83.2 (5.8) 83.4 (5.0) 0.21 72 0.8348
N ACC, right 82.6 (4.9) 84.0 (6.9) 0.97 65 0.3342
N CC, genu 104.6 (14.4) 101.7 (15.4) 0.82 72 0.4122
FA=fractional anisotropy, ADC=apparent diffusion coefficient, SFG=superior
frontal gyrus, MFG=middle frontal gyrus, ACC=anterior cingulate cortex,
CC=corpus callosum. All results presented as mean (standard deviation). All tests
reported using two-tailed pooled t-tests, except when unequal variances were
present, in which case a Satterthwaite t-test was used.
doi:10.1371/journal.pone.0003267.t002
Table 3. Relationship between FA values and remission in
multivariate models.
Regional FA value Estimate SE Test Result (Z-score) p value
SFG, left 0.0099 0.0036 2.72 0.0064
SFG, right 0.0068 0.0030 2.25 0.0244
MFG, left 0.0007 0.0032 0.20 0.8405
MFG, right 0.0050 0.0043 1.16 0.2476
ACC, left 0.0079 0.0036 2.18 0.0290
ACC, right 0.0088 0.0036 2.42 0.0156
CC, genu 0.0035 0.0028 1.26 0.2080
FA=fractional anisotropy; SFG=superior frontal gyrus; MFG=middle frontal
gyrus; ACC=anterior cingulate cortex; CC=corpus callosum. Models examined
remission of depression as the dependent variable, with FA, age, sex, baseline
depression severity and medical comorbidity as independent variables.
doi:10.1371/journal.pone.0003267.t003
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diffusion perpendicular to the direction of the fiber, while integrity
of axonal structures such as microtubules may be associated with
diffusion parallel to the fiber [41–43], both of which contribute to
the overall FA value. Additionally, there appears to be significant
heterogeneity in white matter fiber tract location and shape [44].
Another methodological difference between the studies is that
our analysis method avoided hyperintense lesions. Hyperintense
lesions are associated with anisotropy changes within their
boundaries [19], but also are associated with widespread changes
in normal appearing white matter [20]. Thus the differences in
anisotropy observed in previous studies [26] may be related to
clusters of hyperintensities, which would result in focal reductions
in anisotropy. The same cannot be said of our current study,
although the more widespread relationship between hyperintensity
volume and DTI measures of normal appearing white matter [20]
would be expected to be observed here.
However, hyperintensities did not likely contribute to our
current findings. As greater hyperintensity severity is associated
with lower FA [19,20], this would imply that greater hyperinten-
sity severity is associated with remission. This conclusion does not
appear likely as those published studies which did find a significant
relationship between hyperintensity volume and treatment out-
comes have all concluded that greater hyperintensity severity is
associated with lower likelihood of remission [3–7].
Other neuropathological differences may contribute to our
findings. Reductions in FA may be related to multiple factors at
the cellular level, including reduced axonal integrity or thinning
myelin, although myelin may play only a modulatory role in
anisotropy measures [17,45]. Depression has been associated with
deficits in neuronal size and density in frontal regions [46,47],
which would hypothetically be related to axonal integrity. This
implies that older individuals who respond more favorably to
antidepressants may have neuronal loss and impaired axonal
integrity in frontal regions, which could result in reduced
anisotropy. This leads to the hypothesis that those who experience
this neuronal loss and altered neural connectivity may be more
responsive to antidepressant medication, either by the effect
antidepressants have on neurotransmitters or through antidepre-
sants’ neurotrophic effects. In contrast, individuals with no
structural connectivity deficits may be more likely to exhibit a
poor response. Functional MRI studies have demonstrated that
depression is characterized by impaired functional connectivity
between cortical and limbic regions, while antidepressant response
is accompanied by improved functional connectivity [48,49]. In
some older individuals, this deficit in functional connectivity may
be secondary to structural changes, and these individuals may
respond to antidepressants better than individuals with functional
connectivity deficits with intact structural connections. This is only
a hypothesis, which can best be examined in the future by
combining DTI and functional neuroimaging with an antidepres-
sant trial.
One study limitation is that we could have added further
covariates to the model as antidepressant remission is associated
with additional factors such as disability, depression history or
length of current depressive episode, and subjective social support.
However, we were also limited by the sample size in the number of
covariates we could include. An additional statistical concern was
that we did not control for multiple comparisons, which increases
the risk of a Type I error. Had we adjusted for multiple
comparisons, the observed differences would not have reached
statistical significance. Finally, neuroimaging limitations include
that neuroimaging was not obtained until after sertraline had been
started. This approach is less optimal than completing MRI before
administering any drug, but one would not expect to see any
changes on structural neuroimaging within a two week time frame,
although such studies have not been done to confirm this.
Additionally, other image analysis techniques such as voxel-based
morphometry could have been used. Although this method has the
advantage of examining the entire brain, it may miss critical
regions of interest and does not necessarily replace a region-of-
interest approach [50].
Our finding that failure to remit to antidepressant treatment is
associated with higher anisotropy in the anterior cingulate cortex
and superior frontal gyrus is contrary to our hypothesis and to
previously published studies. However, the finding appears robust
despite the study’s limitations. The discrepancy across studies may
reflect limitations of DTI, but may also reflect population
heterogeneity – either in the depressed geriatric population, or
heterogeneity in white matter structure more broadly. As such, it
requires replication and emphasizes the need for larger-scale
studies examining neuroanatomic correlates of antidepressant
response which are linked to functional imaging studies examining
functional connectivity between frontal and limbic brain regions.
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